270 related articles for article (PubMed ID: 37565281)
1. PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects.
Parghane RV; Basu S
Expert Rev Anticancer Ther; 2023; 23(9):959-975. PubMed ID: 37565281
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
3. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
6. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
7.
Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
[TBL] [Abstract][Full Text] [Related]
8. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
9. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
10. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
12. Update on radioligand therapy with
Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
[TBL] [Abstract][Full Text] [Related]
13. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
14. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
15. Overall survival with [
Hofman MS; Emmett L; Sandhu S; Iravani A; Buteau JP; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; Stockler MR; Williams SG; Martin AJ; Davis ID;
Lancet Oncol; 2024 Jan; 25(1):99-107. PubMed ID: 38043558
[TBL] [Abstract][Full Text] [Related]
16.
Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
Front Oncol; 2022; 12():835956. PubMed ID: 35402274
[TBL] [Abstract][Full Text] [Related]
17. [
Satapathy S; Sahoo RK; Bal C
J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
[TBL] [Abstract][Full Text] [Related]
18. Lutetium-177-PSMA-617: A Vision of the Future.
Chandran E; Figg WD; Madan R
Cancer Biol Ther; 2022 Dec; 23(1):186-190. PubMed ID: 35220877
[TBL] [Abstract][Full Text] [Related]
19. Effect of External Cooling on
Yilmaz B; Nisli S; Ergul N; Gursu RU; Acikgoz O; Çermik TF
J Nucl Med; 2019 Oct; 60(10):1388-1393. PubMed ID: 30850503
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
